Watson Pharmaceuticals, Inc.' Transdermal Therapy For Urge Incontinence Approved For Marketing In The European Union

CORONA, Calif., June 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the European Union's Commission of the European Communities has granted marketing authorization to Watson's oxybutynin transdermal product for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with unstable bladder.

Approval of the application, filed by Watson's wholly-owned European subsidiary, results in a single Marketing Authorization with unified labeling that is immediately valid in all 25 EU-Member States.

On September 24, 2003, Watson announced that it had entered into a marketing and supply agreement with UCB Pharma, pursuant to which UCB Pharma will market the oxybutynin transdermal product in Europe. UCB Pharma expects to launch the product in the fourth quarter 2004. Watson currently markets the product in the United States under the name OXYTROL(R).

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com/.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2003, and its 10-Q for the quarter ended March 31, 2004.

OXYTROL is a registered trademark of Watson Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.

CONTACT: investors, Patty Eisenhaur, +1-909-493-5611, or media, ChrisEso, +1-909-493-4013, both of Watson Pharmaceuticals, Inc.

Back to news